Background Dose intensifi cation with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diff use large B-cell lymphoma compared with CHOP every 3 weeks. We investigated whether this survival benefi t from dose intensifi cation persists in the presence of rituximab (R-CHOP) in all age groups.
Introduction
Diff use large B-cell lymphoma represents more than 30% of all diagnoses of non-Hodgkin lymphoma. 1 Combination chemotherapy with cyclophosphamide, doxorubicin, vin cristine, and prednisolone (CHOP) was established as a standard treatment almost 40 years ago. Intensive regi mens have not consistently improved outcomes compared with CHOP every 3 weeks (CHOP-21), includ ing the use of high-dose treatment plus autologous stem-cell transplant.
2, 3 However, in 2004, the results of the German High-Grade Lymphoma Study Group phase 3 study showed superior overall survival (OS) with six cycles of CHOP every 14 days (CHOP-14) compared with six cycles of CHOP-21 in patients aged 60 years and older, 4 although these results were not replicated in a smaller Japanese study of eight cycles of CHOP-14 versus CHOP-21 in patients with aggressive non-Hodgkin lymphoma, only 58% of whom had diff use large B-cell lymph oma. 5 Incorporation of etoposide into CHOP improved response rates and event-free survival in young patients, but did not aff ect overall survival in any age group. 4 , 6 An alternative dose-intense regimen of cyclophosphamide, vindesine, bleomycin, and prednisolone followed by high-dose metho trexate, ifosfamide, and cytarabine (ACVBP) also improved survival compared with standard CHOP-21 in both localised disease and poor-prognosis aggressive non-Hodgkin lymphoma but the results did not change clinical practice, probably due to toxicity of the polydrug com bination. 7, 8 Concurrent with these results, rituximab, an anti-CD20 monoclonal antibody, combined with CHOP-21 improved cure rates by 10-15% compared with CHOP-21 alone without serious additional toxicity in the pivotal phase 3 Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial; 9,10 the results were confi rmed in a sub sequent US intergroup study. 11 Rituximab also added benefi t to CHOP-14 (R-CHOP-14) in patients older than 60 years in the RICOVER-60 trial, 12 and in young patients (aged 18-60 years) with a good prognosis in the MiNT study. 13 However, whether the improved survival reported with CHOP-14 by the German group 4 was still evident in patients receiving rituximab remained uncertain. Therefore, in 2005, the UK National Cancer Research Institute Lymphoma Clinical Study Group commenced a large, randomised study of all patients older than 18 years with previously untreated diff use large B-cell lymphoma to compare CHOP-14 with CHOP-21 in patients receiving rituximab. This phase 3, open-label randomised study was designed to detect superior OS of the dose-intense regimen R-CHOP-14 versus standard R-CHOP-21 in patients of all age groups and all risk strata.
Methods Patients
In this phase 3 study, patients with diff use large B-cell lymphoma were enrolled in 119 centres in the UK. Eligible patients were aged 18 years and older with previously untreated, histologically confi rmed, diff use large B-cell lymphoma according to the WHO classification. 14 Patients were required to have Ann Arbor bulky stage IA (tumour mass diameter >10 cm) or stage IB-IV disease, a good performance status (WHO grade 0-2), adequate cardiac, renal, hepatic, and haematological func tion (initial neutrophil count >1·5 × 10⁹ per L, initial platelet count >100 × 10⁹ per L unless the abnormality was caused by lymph oma rather than another disease in which case the patient was eligible). Patients with T-cell lymphomas, transformed follicular lymphoma, or a history of indolent lymphoma were excluded. However, patients with previously undiag nosed concurrent smallcell infi ltration in bone marrow or lymph node were eligible. Patients with CNS involvement, positive serology for HIV, hepatitis B or hepatitis C virus, a history of heart failure or uncontrolled angina pectoris, active malignancy in the preceding 10 years, or other illnesses precluding administration of study treatment were ineligible.
The trial was overseen by a trial steering committee and an independent data monitoring committee. 
Randomisation and masking
Randomisation was done centrally by the Cancer Research UK and University College London Cancer Trials Centre, London, UK, using a minimisation procedure, stratifi ed for international prognostic index (IPI) and centre. Patients were allocated in a one-to-one ratio to R-CHOP-21 or R-CHOP-14 regimens. The trial was not masked.
Procedures
The R-CHOP-21 regimen was based on the original doses used by the GELA group 9 and consisted of intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1·4 mg/m² (maximum dose 2 mg), rituximab 375 mg/m² on day 1, and oral prednisolone 40 mg/m² on days 1-5, administered every 21 days for a total of eight cycles. R-CHOP-14, designed by the German High Grade Lymphoma Study Group, 4 consisted of intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 2 mg, rituximab 375 mg/m² on day 1, and oral prednisolone 100 mg on days 1-5, administered every 14 days for six cycles followed by two further infusions of rituximab 375 mg/m² on day 1 every 14 days. The recombinant human granulocyte-colony stimulating factor (G-CSF) lenograstim was administered on days 4-12 of each cycle to patients randomly assigned to R-CHOP-14 whereas use of G-CSF for patients receiving R-CHOP-21 was at the discretion of the investigators. All patients received allopurinol 300 mg/day for the fi rst cycle and co-trimoxazole 480 mg twice daily for 3 days per week until 2 weeks after the end of treatment. Other suppor tive medications were given according to local proto cols. Prophylaxis for CNS relapse was at the dis cretion of the investigators; however, the recom mendation was that patients with large-cell lymphoma involvement of the bone marrow, peripheral blood, nasal or paranasal sinuses, orbit, and testis receive 12·5 mg intrathecal methotrexate for the fi rst three cycles of treatment, administered as per local guidelines. Consoli dation radiotherapy was also permitted at the discretion of the investigators.
Patients were assessed before treatment; at each attendance for treatment; and then after treatment every 3 months until 1 year, then every 6 months until 2 years, and thereafter every year. Reports by clinicians included details of treatment and adverse eff ects, performance status, and results of blood counts and other relevant tests. CT scans of the chest, abdomen, pelvis, with or without neck were done at baseline, after four cycles of chemotherapy, at the end of treatment, and at 3 months and 12 months after completion of treatment. In the event of clinical suspicion of relapse, additional imaging was done. ¹⁸F-fl uorodeoxyglucose (¹⁸F-FDG) PET scans were not mandated and therefore no PET data were gathered as part of the main study.
Central pathology review was done by an expert haematopathologist (AJ). A full immunohistochemical panel was done for all available specimens and included CD20, CD79a, P53 expression, and the proliferation index (MIB1). Molecular phenotype (germinal centre vs non-germinal centre) was determined using the Hans criteria. 15 Fluorescence in-situ hybridisation (FISH) was done according to reported methods 16 to detect MYC, BCL6, and BCL2 rearrangements.
Statistical analysis
The primary outcome was OS. The secondary outcomes were progression-free survival (PFS), toxicity, and response rate. The method of analysis was intention to treat.
The sample size was based on an estimated 2-year OS of 70% in the R-CHOP-21 group; the aim in the trial Data are number, number (%), or n/N (%). R-CHOP-21=cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days. R-CHOP-14=cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 14 days. was to detect an improvement of 8% (from 70% to 78%) with R-CHOP-14. With 5% signifi cance and 90% power (two-sided), a total of 330 OS events were needed. The plan was to randomly assign a total of 1080 patients over 3 years. The required number of OS events was expected to occur 1 year after the last patient was randomly assigned. The total number of OS events reported (n=182) 1 year after the completion of recruitment was much lower than expected; therefore, the statistical plan was amended on the basis of the estimates from the combined groups without formal comparisons between groups: the estimated 2-year OS in the R-CHOP-21 group was about 75-80%, and a total of 233 OS events would be needed to detect a 7-8% diff erence in OS with 5% signifi cance level and 90% power. The amendment was approved by the steering committee and independent data monitoring committee.
OS was calculated from the date of randomisation until the date of death from any cause; patients still alive were censored at the date they were last known to be alive.
PFS was calculated from the date of randomisation to the date of fi rst appearance of disease progression, relapse, or death from any cause; patients alive without progression or relapse were censored at the date they were last known to be alive.
Response was assessed by the local treating physician as complete response (CR), unconfi rmed complete response (CRu), partial response (PR), stable disease, or progressive disease (PD) in accordance with the International Workshop Standardized Response Criteria for Non-Hodgkin Lymphoma. 17 The severity of adverse events was defi ned according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 3.0).
The log-rank test was used to compare the KaplanMeier curves for OS and PFS. The χ² test for interaction or trend was used to ascertain the diff erences in the benefi ts of R-CHOP-14 in diff erent patients subgrouped according to baseline characteristics. The response achieved during treatment was compared by use of the Mann-Whitney test. Patients who received at least one cycle of assigned protocol treatment were included in the safety analyses. Cox regression model was applied in the prognostic analyses. All p values were two-sided.
This study is registered, number ISCRTN 16017947.
Role of the funding source
The trial sponsor (University College London) was responsible for randomisation, data gathering, entry, and validation, monitoring procedures, reporting of serious adverse events, organisation of central patho logical review, liaison with investigators, statistical analysis, and production of the report. Chugai Pharma ceutical had no role in study design, data gathering or interpretation, statistical analysis, or the writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
From March, 2005, to November, 2008, 1080 patients were randomly assigned to treatment (540 in each group). Nine patients did not commence treatment due to consent withdrawal, illness, or death (fi gure 1). Baseline characteristics of patients, including IPI, were well balanced between groups (table 1) . 937 patients (459 in R-CHOP-21 group and 478 in R-CHOP-14 group) had central pathology review; up to 560 patients (275 and 285, respectively) were assessable for molecular characteristics and the groups were also well balanced (table 1) . 422 (78%) of 540 patients completed all eight cycles of R-CHOP-21 and 476 (88%) of 540 completed per-protocol R-CHOP-14; 91% in each group (489 in R-CHOP-21 group and 494 in R-CHOP-14 group) completed at least six cycles. Table 2 shows that the percentages for the median total dose received for each drug by treatment group were similar in the R-CHOP-21 and R-CHOP-14 groups; the median dose intensities achieved for each drug by treatment group were also similar with the exception of vincristine. In the R-CHOP-21 group, 420 (78%), 417 (77%), 439 (81%), 371 (69%), and 432 (80%) patients received at least 80% of the planned total dose of cyclosphosphamide, doxorubicin, prednisolone, vincristine, and rituximab, respectively. In the R-CHOP-14 group, 497 (92%), 494 (91%), 500 (93%), 444 (82%), and 469 (87%) patients received at least 80% of the planned total dose of cyclosphosphamide, doxo rubicin, prednisolone, vincristine, and rituximab, respec tively. The median dose intensity for individual drugs in the R-CHOP-14 group relative to the R-CHOP-21 group was 152% for cyclophosphamide, 152% for doxorubicin, 148% for vincristine, 191% for prednisolone, and 151% for rituximab. All 540 patients in the R-CHOP-14 group received G-CSF as per-protocol treatment; 293 (54%) of 540 pa tients in the R-CHOP-21 group were given G-CSF as secondary prophylaxis. 54 (10%) patients in the R-CHOP-21 group and 51 (9%) in the R-CHOP-14 group underwent radiotherapy after chemotherapy.
Response after four cycles was assessable in 981 (91%) of 1080 patients, with CR or CRu documented in 169 (34%) of 490 patients in the R-CHOP-21 group and 159 (32%) of 491 in the R-CHOP-14 group. End-of-treat ment response was assessable in 1002 (93%) patients who received at least one cycle of treatment. CR or CRu at the end of treatment, as assessed by use of CT scanning, was noted in 63% of patients in the R-CHOP-21 group and 58% of those receiving R-CHOP-14 (p=0·1830; table 3). The diff erence in overall response rate between treatment groups was not signifi cant (88% patients in R-CHOP-21 group vs 91% in R-CHOP-14 group; p=0·1223; table 3).
At the time of the analysis, median follow-up was 46 months (IQR 35-57). The 2-year PFS was 74·8% (95% CI 71·0-78·4) in the R-CHOP-21 group and 75·4% (71·8-79·1) in the R-CHOP-14 group (fi gure 2A). 14 (1%) CNS relapses (eight in R-CHOP-21 group and six in R-CHOP-14 group) were reported, with isolated recurrences in seven of these patients (four [<1%] in the R-CHOP-21 group and three [<1%] in the R-CHOP-14 group). The 2-year OS was 80·8% (77·5-84·2) in the R-CHOP-21 group and 82·7% (79·5-85·9) in the R-CHOP-14 group (fi gure 2B).
By use of the Cox regression model for prognostic factor analysis with both groups combined, a higher IPI was associated with worse OS: IPI 4 or 5 versus 0-3 (hazard ratio [HR] 2·15, 95% CI 1·63-2·83; p<0·0001). Multi variate Cox regression analysis of individual prognostic factors, including age as a continuous variable, showed that age (p<0·0001), stage (p=0·0007), WHO performance status (p<0·0001), raised lactate dehydrogenase con centration (p=0·0007), and presence of B symptoms (p=0·0486) were independent prognostic factors (p<0·05 deemed signifi cant).
According to the results of the molecular analysis, MYC rearrangement (n=36) was prognostic for OS (2-year OS, MYC-rearranged 75%, 95% CI 60·7-89·0, vs MYCnormal 85%, 80·7-88·6; HR 2·08, 1·15-3·78; p=0·0160) and when adjusted for age, sex, stage, presence of B symptoms, bulky disease, WHO performance status, and raised lactate dehydrogenase concentrations, survival was non-sig nifi cantly worse (1·71, 0·92-3·18; p=0·0875). The so-called double-hit mutation (both MYC and BCL2 re arrange ments; n=16) was non-signifi cantly prognostic for 2-year OS (double-hit 63%, 38·8-86·1, vs no doublehit 84%, 80·5-88·3; 2·24, 95% CI 0·98-5·17; p=0·0575), which was main tained in the multivariate analysis (2·03, 0·87-4·73; p=0·1023). No other assess ments with immuno histochemistry or FISH were prog nostic for 2-year OS, including germinal centre versus nongerminal centre phenotype, MIB1, P53 expression, and BCL6 and BCL2 rearrange ments (appendix pp 1-4).
In a planned subgroup analysis, no factor was predictive for a survival benefi t of R-CHOP-14 versus R-CHOP-21 (fi gures 3, 4) including age, sex, stage, presence of B symptoms, bulky disease, WHO performance status, raised lactate dehydrogenase concentrations, or features of aggressive disease such as high proliferation rate and high IPI, although the probability of survival was non-signifi cantly in favour of R-CHOP-21 in the subgroup with MIB1 of at least 90% (HR 2·09, 95% CI 0·87-5·00, p=0·06). None of the gene abnormalities detected by use of FISH, including MYC rearrangement and the double-hit mutation status, or 255 people died, 134 in the R-CHOP-21 group (85 lymphoma-related, three treatment-related, nine secon dary malignancies, eight cardiac causes, 25 other illnesses, and four unknown causes) and 121 in the R-CHOP-14 group (79 lymphoma-related, nine treatment-related, six secondary malignancies, six cardiac causes, 17 other illnesses, and four unknown causes; appendix p 5). All cardiac deaths occurred at least 3 months after completion of treatment.
Frequencies of grade 3 or 4 neutropenia and febrile neutropenia were signifi cantly higher with R-CHOP-21, probably due to the reduced use of G-CSF, whereas grade 3 or 4 thrombocytopenia was signifi cantly higher in the R-CHOP-14 group (table 4). Of 422 patients in the R-CHOP-21 group who received eight cycles of treat ment, 303 (72%) had a toxicity of grade 3 or greater from cycles one to eight, and 282 (67%) from cycles one to six, and 21 (5%) from cycles seven to eight. 13 grade 5 toxicities were reported-neutropenic sepsis (one in R-CHOP-21 group and one in R-CHOP-14 group), non-neutropenic sepsis (one and two, respectively), suicide (two in R-CHOP-21 group), renal failure (one in R-CHOP-14 group), multi organ failure (one in R-CHOP-14 group), and not specifi ed (four in R-CHOP-14 group).
Discussion
The primary endpoint of superior overall survival with R-CHOP-14 compared with R-CHOP-21 was not met, and R-CHOP-14 did not improve response rates, PFS, or safety despite preservation of dose intensity. The two regimens were similar in all effi cacy endpoints; however, the study was not powered to detect non-inferiority.
Similar results were presented at the 2012 American Society of Clinical Oncology conference by the GELA group from their study of 602 patients aged 60-80 years. 18 Patients were randomly assigned to eight cycles of either R-CHOP-14 or R-CHOP-21; however, G-CSF was adminis tered at the investigator's discretion in both groups, resulting in a reduced dose intensity of doxorubicin and cyclophos phamide in the R-CHOP-14 group compared with the dose intensity in our study, and that of the original German reports. 4, 6 The smaller GELA study was powered for superiority and the results showed no diff erence in event-free survival, PFS, OS, response rate, or safety, supporting our fi ndings. 18 Of note, in routine clinical practice many patients now receive only six cycles of R-CHOP.
In our study, toxicities in the two groups were similar; R-CHOP-14 was associated with signifi cantly more thrombocytopenia than was R-CHOP-21, but less neutropenia because of G-CSF primary prophylaxis. Treatmentrelated deaths were numerically higher in the R-CHOP-14 group (nine vs three); however, the diff erence was not signifi cant (p=0·082). Few studies have shown a benefi t of dose intensification with incorporation of rituximab versus standard rituximab-chemotherapy combinations, despite the targeting of high-risk populations. [19] [20] [21] [22] In a younger population, improved effi cacy with the addition of etoposide to CHOP-14 was lost when combined with rituximab. 13 First-line high-dose chemotherapy plus rituximab followed by autologous stem-cell transplant has also not improved outcomes compared with rituximab-chemotherapy alone. 23, 24 By contrast, in a study by the GELA group, 25 a signifi cant survival advantage was reported with R-ACVBP compared with R-CHOP-21 in 380 young patients with low-risk or low-intermediate-risk disease. After a median follow-up of 44 months, the 3-year eventfree survival was 81% in the R-ACVBP group compared with 67% with R-CHOP-21, and 3-year PFS was 87% and 73%, respectively. However, this improve ment was associated with a three times increase in serious adverse events in the experimental group and febrile neutropenia in 38% of patients, despite G-CSF prophyl axis, versus 7% with R-CHOP-21. In the Comment accompanying this GELA trial, the recom mendation was that R-ACVBP should not be off ered routinely until high-risk groups can be accurately iden tifi ed to justify the additional toxicity. 26 Of note, the 2-year PFS was 80% in patients in our study who were younger than 60 years with IPI 0-2 receiving R-CHOP-21.
Molecular features such as high proliferation index, P53 deletion, and BCL2, MYC, and BCL6 rearrange ments have previously been identifi ed as poor prognostic markers in retrospective or small series. 16, [27] [28] [29] In this study, only MYC rearrangement (10% of patients) was a poor prognostic marker in the univariate analysis but was not predictive for benefi t of R-CHOP-14. Double-hit diff use large B-cell lymphomas are known to have a worse prognosis, 16, [30] [31] [32] and although, in our study, this group of patients had poorer survival, in the multivariate analysis the diff erence was not signifi cant and the eff ect of doublehit rearrangements might have been over estimated in previous retrospective studies. Molecular analysis showed no other poor prognostic subgroup or a cohort that benefi ted from R-CHOP-14. This fi nding was also refl ected in the absence of sig nifi cantly improved outcomes from R-CHOP-14 in patients with high IPI. With respect to the cell of origin, germinal centre diff use large B-cell lymphoma has also been reported to have a better prognosis than does the non-germinal centre type; 27, [33] [34] [35] although a diff erence was not noted in our study, the Hans criteria method for determination of the cell of origin is inferior to gene expression profi ling. Never theless, while the tissue used was of suitable quality for defi nition of the immunophenotype in only 50% of cases, this analysis is one of the largest undertaken within a prospective trial.
R-CHOP-14 has effi cacy in patients with diff use large B-cell lymphoma (panel). However, it is not superior to standard R-CHOP-21 and this trial was not powered to show non-inferiority of R-CHOP-14 to R-CHOP-21; therefore, R-CHOP-21 remains the standard reference regimen. Results of the biomarker analysis and clinical stratifi cation did not identify a subgroup of patients who would benefi t from a more intensifi ed regimen.
Contributors DC designed the study, had study oversight, and contributed to data interpretation, writing, and approval of the report. EAH did the data gathering, analysis, and interpretation, literature searches, and wrote the report. AJ designed the study, and did the central histological review and molecular analysis. WQ designed the study, analysed and interpreted data, produced fi gures, and wrote the report. PS, PM, and JG gathered, interpreted, and analysed the data. CP, KMA, JAR, AM, JD, DT, AK, PJ, and DL gathered and interpreted the data. DC and EAH contributed equally. All authors have reviewed and approved the fi nal version of the report. The benefi t of combination rituximab and CHOP-14 12, 13 (cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 14 days) or CHOP-21 (cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days) was reported in four randomised studies, 9, 11 and CHOP-14 was compared with CHOP-21 in two phase 3 trials. 4, 6 The comparison of R-CHOP-14 and R-CHOP-21 in a study of elderly people showed no benefi t of dose intensifi cation; however, many patients received dose reductions in the R-CHOP-14 group. 18 R-CHOP-14 and R-CHOP-21 have not been compared in a large cohort study with inclusion of all patient and disease subgroups, and maintenance of dose intensity in both chemotherapy regimens.
Interpretation
Reports of studies have consistently shown the benefi t of adding the anti-CD20 monoclonal antibody rituximab to CHOP in previously untreated diff use large B-cell lymphoma, irrespective of the population assessed. Before the introduction of rituximab into the routine care of patients with diff use large B-cell lymphoma, the fi ndings of several reports showed a benefi t of dose-intensifi ed regimens compared with standard CHOP, including CHOP-14, rather than CHOP-21. The results of our randomised, phase 3 study of the comparison of R-CHOP-14 with R-CHOP-21 in 1080 patients from all prognostic groups showed that R-CHOP-14 is not superior to R-CHOP-21; therefore, in the era of rituximab, R-CHOP-21 remains the standard fi rst-line treatment for diff use large B-cell lymphoma.
